| Analysis of menstrual calendars and serum alpha 2-PEG in women on hormone replacement therapy for 12 months. | |
| | |
MedLine Citation:
|
PMID: 7821501 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study was conducted to assess endometrial protection in women on a cyclical combined hormone replacement regimen with 1 mg norethisterone BP, and to evaluate the use of the bleeding pattern and serum alpha 2-PEG in monitoring the endometrial response to exogenous hormone therapy. Fifty-one postmenopausal women attending the Menopause Research Unit at Leicester Royal Infirmary, UK, completed the study. All patients were at least 1 year after the menopause, with an average of 26 months since the last menstrual period. All women were prescribed a regimen of two tablets of Hormonin (oestriol 0.27 mg, oestrone 1.4 mg, and oestradiol 0.6 mg) continuously, with 1 mg of norethisterone added for 12 days out of each 28-day treatment cycle. Menstrual diaries were collected and analysed. The secretory changes were assessed by histology, menstrual bleeding pattern and a biological marker of secretory activity (alpha 2-PEG). Withdrawal bleeding occurred on average on days 11, 12, 11, 12 and 13 on months 2, 3, 6, 9 and 12, respectively. There was a poor degree of consistency in the bleeding pattern. The level of alpha 2-PEG increased from the average baseline measurement of 2.7 ng/ml (S.D., 4.12) to 8.5 ng/ml (S.D., 4.16) after progestogen treatment. This rise, although significant, did not correlate with the uterine bleeding pattern. There was no statistically significant correlation between the level of alpha 2-PEG and endometrial histology. The findings highlight the fact that cycle predictability on HRT, as exemplified in this regimen, is poor. The level of alpha 2-PEG is a poor predictor of the endometrial histology and has a poor correlation with the day of onset of bleeding. |
| | |
Authors:
|
M Habiba; F al-Azzawi |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of obstetrics, gynecology, and reproductive biology Volume: 57 ISSN: 0301-2115 ISO Abbreviation: Eur. J. Obstet. Gynecol. Reprod. Biol. Publication Date: 1994 Oct |
Date Detail:
|
Created Date: 1995-02-14 Completed Date: 1995-02-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0375672 Medline TA: Eur J Obstet Gynecol Reprod Biol Country: IRELAND |
Other Details:
|
Languages: eng Pagination: 37-42 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynaecology, Leicester University School of Medicine, Leicester Royal Infirmary, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Estrenes / therapeutic use* Estrogen Replacement Therapy* Female Glycoproteins* Humans Menstrual Cycle / drug effects, physiology* Menstruation / physiology Middle Aged Norethindrone / therapeutic use* Patient Compliance Postmenopause / blood* Pregnancy Proteins / blood* Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Estrenes; 0/Glycoproteins; 0/PAEP protein, human; 0/Pregnancy Proteins; 68-22-4/Norethindrone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Three cases of sarcoma occurring after radiation therapy of breast cancers.
Next Document: Increased phagocytic activity of polymorphonuclear leukocytes during pregnancy.